glp-1 employer healthcare costs spending in 2025: Why it's likely to accelerate Today in #Employer Coverage: GLP-1

The state obesity drug coverage landscape will continue to evolve as states respond to the recent announcement of the BALANCE model (see Box 1) and as states contend with budget challenges and the federal Medicaid spending cuts in the 2025 reconciliation law

Clark and others in the Cardiometabolic space predict that we will soon have more conclusive evidence that GLP-1s are effective in in a variety of other health issues, too

This story originally appeared in the May 4, 2026 issue of Woman's World

In addition to , and cells in the pancreas, the receptor has been found in a variety of other tissues, including the intestine, stomach, lungs, heart, kidneys and several regions of the central nervous system (Holst et al., 2019